Introduction: The MANIFEST-2 trial is a pivotal phase 3 study evaluating the combination of pelabresib, a bromodomain and extraterminal domain (BET) inhibitor, with ruxolitinib, a Janus kinase (JAK) inhibitor, in patients with myelofibrosis who have not previously received JAK inhibitor therapy (1). Myelofibrosis is a progressive haematological mal
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
Safe Ramadan Practices during COVID-19 - WHO Guidance
4873 Reached8 Comments3 Likes
Vildagliptin in Reducing Risk of Post-partum Diabetes
2383 Reached7 Comments4 Likes